Health · Pharma & Biotech · 10 hrs ago
Bristol Myers lung disease drug meets main goal in late-stage trial
Bristol Myers’ drug for lung disease met the main goal in a late-stage trial.
The trial was described as late-stage.
The information available does not name the drug.
It does not specify which lung disease the drug targets.
It gives no details about the trial’s results beyond meeting its main goal.
It does not say what Bristol Myers plans to do next.
Bristol Myers’ lung disease drug met the main goal in a late-stage trial.
The report does not identify the drug.
The report does not state what the trial’s main goal was.
Reuters published the report on October 12, 2026.
- Who
- Bristol Myers.
- What
- Its lung disease drug met the main goal in a late-stage trial.
- When
- Reuters published the report on October 12, 2026. The trial date is not stated.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- Bristol Myers
- Drug area
- Lung disease
- Trial stage
- Late-stage
- Report date
- October 12, 2026
Sources
Related news
Bimatoprost eye lens shows early promise for cataracts and glaucoma
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Merck’s eye drug meets main study goal, but results are mixed
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
